Shares of Enovis Co. (NYSE:ENOV – Get Free Report) reached a new 52-week low during trading on Thursday . The stock traded as low as $34.44 and last traded at $37.00, with a volume of 1324867 shares changing hands. The stock had previously closed at $37.18.
Wall Street Analysts Forecast Growth
Separately, Needham & Company LLC reissued a “buy” rating and set a $64.00 price objective on shares of Enovis in a research note on Wednesday.
Read Our Latest Research Report on Enovis
Enovis Trading Down 0.5 %
Enovis (NYSE:ENOV – Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.06. The business had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. Equities research analysts predict that Enovis Co. will post 2.79 EPS for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. Aster Capital Management DIFC Ltd acquired a new position in Enovis in the fourth quarter valued at $29,000. Quadrant Capital Group LLC grew its holdings in Enovis by 53.0% in the 4th quarter. Quadrant Capital Group LLC now owns 690 shares of the company’s stock valued at $30,000 after buying an additional 239 shares during the period. UMB Bank n.a. increased its stake in shares of Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after acquiring an additional 437 shares during the last quarter. Pinnacle Bancorp Inc. lifted its holdings in shares of Enovis by 54.5% during the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after acquiring an additional 300 shares during the period. Finally, Quarry LP boosted its position in shares of Enovis by 506.1% in the fourth quarter. Quarry LP now owns 897 shares of the company’s stock worth $39,000 after acquiring an additional 749 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.
Enovis Company Profile
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Read More
- Five stocks we like better than Enovis
- Find and Profitably Trade Stocks at 52-Week Lows
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- How to Invest in Blue Chip Stocks
- The 3 Most Talked About Investments on WallStreetBets Right Now
- Earnings Per Share Calculator: How to Calculate EPS
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.